EU reporting continues to show worrying discrepancies
This article was originally published in Clinica
Executive Summary
The EU still has a long way to go before it can claim that criteria for the reporting of medical device incidents is the same in each of the member states, including those that joined the EU on May 1. A quick glance at the recently updated chart on the website of the European Commission's medical devices unit reveals many gaps and raises questions which could be seen as undermining this most critical element in the medical device regulatory armoury.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.